Loading data for VOR — first visit, this takes a few seconds.

Alerta

Vor Biopharma Inc. (VOR)

NasdaqGS: VOR · Precio en tiempo real · USD

23.58

+0.30 (1.29%)

Al cierre: Aug 18, 2026, 3:59 PM

23.58

+0.00%

Fuera de horario: 4:00 PM

1.29% (1D)

Precio de compra	n/a
Capitalización de mercado	1.4B
Ingresos (TTM)	n/a
Beneficio neto (TTM)	627.78M
Beta	1.72
EPS (TTM)	180.58
Ratio PER (TTM)	0.13
Adelante PE	-6.51
P/B (TTM)	-8.49
P/S (TTM)	n/a
Earnings Date	Nov 12, 2026

Precio de venta	n/a
Volumen	1,027,209
Volumen medio (20D)	1,172,406
Abierto	24.05
Anterior Cerrar	23.28
Rango del día	23.56 - 24.54
Rango de 52 semanas	6.50 - 50.20
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de VOR

Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, ...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Feb 5, 2021

Empleados 76

Bolsa de Valores NasdaqGS

Símbolo bursátil VOR

Sitio web https://www.vorbio.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Vor Biopharma fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -695.98M, un aumento de 495.29%.

Estados financieros

Sorpresa de resultados

Vor Biopharma ha publicado sus resultados trimestrales en Aug 11, 2026:

Ingresos de $0 falla las estimaciones por $0, con NaN% Crecimiento interanual.

EPS de -0.8 falla las estimaciones por -0.10, con 99.68% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Vor Biopharma Inc. publique sus resultados el Nov 12, 2026, durante el horario de mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

1 mes hace · Simply Wall St.

Why Vor Biopharma (VOR) Is Up 24.5% After Broad FTSE Russell Index Inclusion And What's Next

In late June 2026, Vor Biopharma Inc. was added to a broad suite of FTSE Russell indices, including the Russell 2000, 2500, 3000, Microcap, and related growth and value benchmarks. This sweeping inclu...

2 meses hace · Motley Fool

Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge

This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors.

2 meses hace · Motley Fool

Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean

Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics.

3 meses hace · Simply Wall St.

We're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

3 meses hace · Zacks

Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade

The consensus price target hints at a 124.6% upside potential for Vor Biopharma (VOR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings est...

Página 1 de 2

Vor Biopharma Inc. (VOR)